Semaglutide vs tirzepatide: what actually differs.
Both medications are used in medical weight management, and both are prescribed only after a provider evaluation. Here is a plain-language comparison of how they work, what they share, and how eligibility is decided — with no assumption that either one is right for you.
Different pathways, similar process.
Semaglutide acts on the GLP-1 receptor. Tirzepatide acts on both the GIP and GLP-1 receptors. Both are commonly given as a once-weekly injection, both are titrated up slowly, and both are approved under specific brand names for type 2 diabetes and, separately, for chronic weight management in qualifying adults.
Neither medication is better in every case. Published studies for each were designed differently, so direct comparisons are limited. What matters clinically is your history, your current medications, your tolerability, availability, and whether treatment is appropriate at all.
A clear comparison.
| Semaglutide | Tirzepatide | |
|---|---|---|
| Medication class | GLP-1 receptor agonist — acts on a single incretin pathway. | Dual GIP and GLP-1 receptor agonist — acts on two incretin pathways. |
| How it is typically taken | Commonly a once-weekly subcutaneous injection, with an oral form available for some approved uses. | Commonly a once-weekly subcutaneous injection. |
| FDA-approved uses | Approved under different brand names for type 2 diabetes and, separately, for chronic weight management in qualifying adults. | Approved under different brand names for type 2 diabetes and, separately, for chronic weight management in qualifying adults. |
| How dosing usually works | Providers typically start low and increase gradually over weeks to help limit side effects. | Providers typically start low and increase gradually over weeks to help limit side effects. |
| Common reported side effects | Nausea, vomiting, diarrhea, constipation, and abdominal discomfort are among the most commonly reported. | Nausea, vomiting, diarrhea, constipation, and abdominal discomfort are among the most commonly reported. |
| Important safety considerations | Both carry labeled warnings and contraindications, including a boxed warning regarding thyroid C-cell tumors in animal studies. Not appropriate for everyone. | Both carry labeled warnings and contraindications, including a boxed warning regarding thyroid C-cell tumors in animal studies. Not appropriate for everyone. |
| How a provider chooses | Based on your health history, current medications, prior treatment response, tolerability, insurance and availability, and applicable regulations. | Based on your health history, current medications, prior treatment response, tolerability, insurance and availability, and applicable regulations. |
This table is educational and is not a substitute for the FDA-approved prescribing information or your provider's guidance. Approved uses, warnings, and availability can change.
How the decision is actually made.
- Your full medical history, including thyroid, pancreatic, and gastrointestinal conditions
- Current medications and supplements, and possible interactions
- Prior experience with GLP-1 or other weight management medications
- Lab work when clinically appropriate
- Tolerability and your ability to follow a gradual dose schedule
- Nutrition, movement, sleep, and behavior support alongside any medication
- Cost, insurance coverage, and current product availability
- Long-term plan, including follow-up and maintenance
Medication is one component of a medical weight management plan. Our providers pair any prescription discussion with nutrition, movement, and behavior guidance, plus regular follow-up to monitor progress and side effects.
Learn more about our medical weight management program or how consultations work.
Semaglutide vs tirzepatide, answered.
Neither medication is universally better. They work on different receptor pathways, and published trials for each medication were designed differently, so head-to-head comparisons are limited. The more useful question is which option, if any, is appropriate for you — and that requires a provider evaluation of your history, medications, labs when appropriate, and goals.
Semaglutide acts on the GLP-1 receptor. Tirzepatide acts on both the GIP and GLP-1 receptors. Both are commonly given as once-weekly injections and both are approved under specific brand names for type 2 diabetes and, separately, for chronic weight management in qualifying adults.
Any change in medication should be made by your prescribing provider. If a medication is not tolerated, is unavailable, or is not producing the expected clinical response, your provider will discuss whether an alternative is appropriate for you and how a transition would be managed.
Hardcore Health provides provider-led telehealth consultations for eligible adults in Florida and Arizona. No medication is guaranteed or prescribed automatically. If treatment is appropriate after evaluation, your provider will review the options, risks, benefits, alternatives, and proper use with you.
Results vary and cannot be predicted for any individual. Outcomes depend on eligibility, dose tolerance, nutrition and activity, other health conditions and medications, and how consistently the plan is followed. Medication is one part of a medical weight management plan, not the whole plan.
No. Compounded products are not FDA-approved and are not evaluated by the FDA for safety, effectiveness, or quality. Your provider can discuss what is appropriate and legally available for your situation.
Medical weight management and prescription medication are not appropriate for everyone. Eligibility and treatment options depend on provider evaluation, medical history, current medications, lab work when clinically appropriate, and applicable laws and regulations. Results vary.
Online appointments are available to eligible patients in Boca Raton, Parkland, Delray Beach, Coral Springs, throughout Florida, and statewide in Arizona.
Your care is provider-led
Meet with Brittany.
Brittany takes time to understand your symptoms, health history, goals, and concerns before recommending next steps.
Treatment is recommended only when determined to be medically appropriate.